[1]
|
Huang, X., Ke, K., Jin, W., et al. (2022) Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. Frontiers in Immunology, 13, Article ID: 887048. https://doi.org/10.3389/fimmu.2022.887048
|
[2]
|
Blondy, S., David, V., Ver-dier, M., et al. (2020) 5-Fluorouracil Resistance Mechanisms in Colorectal Cancer: From Classical Pathways to Promising Processes. Cancer Science, 111, 3142-3154. https://doi.org/10.1111/cas.14532
|
[3]
|
Shiga, T. and Hiraide, M. (2020) Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Current Treatment Options in Oncology, 21, 27. https://doi.org/10.1007/s11864-020-0719-1
|
[4]
|
Feng, A.W., Guo, J.H., Gao, S., et al. (2022) A Randomized Phase II Trial of Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed versus Oxaliplatin plus 5-Fluorouracil for Unresectable Colorectal Cancer Liver Metastases. Frontiers in Oncology, 12, Article ID: 913017. https://doi.org/10.3389/fonc.2022.913017
|
[5]
|
Van Cutsem, E. (1998) Raltitrexed (Tomudex). Expert Opinion on Investigational Drugs, 7, 823-834.
https://doi.org/10.1517/13543784.7.5.823
|
[6]
|
Zhao, H., Zhang, Y., Sun, J., et al. (2016) Raltitrexed Inhibits HepG2 Cell Prolif-eration via G0/G1 Cell Cycle Arrest. Oncology Research, 23, 237-248. https://doi.org/10.3727/096504016X14562725373671
|
[7]
|
Ding, W.X., Liu, S., Ma, J.X., et al. (2019) Raltitrexed Increases Radiation Sensitivity of Esophageal Squamous Carcinoma Cells. Cancer Cell International, 19, 36. https://doi.org/10.1186/s12935-019-0752-y
|
[8]
|
Hu, C., Chen, X., Lin, X., et al. (2022) Raltitrexed Regulates Proliferation and Apoptosis of HGC-27 Cells by Upregulating RSK4. BMC Pharmacology & Toxicology, 23, 65. https://doi.org/10.1186/s40360-022-00605-2
|
[9]
|
Liang, H., Hu, C., Lin, X., et al. (2020) MiR-548d-3p Promotes Gastric Cancer by Targeting RSK4. Cancer Management and Research, 12, 13325-13337. https://doi.org/10.2147/CMAR.S278691
|
[10]
|
Ye, Q., Wang, X., Jin, M., et al. (2018) Effect of RSK4 on Biological Characteristics of Colorectal Cancer. World Journal of Surgical Oncolo-gy, 16, 240. https://doi.org/10.1186/s12957-018-1474-7
|
[11]
|
Zhen, H., Li, G., Zhao, P., et al. (2020) Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. OncoTargets and Therapy, 13, 12325-12339.
https://doi.org/10.2147/OTT.S276125
|
[12]
|
Köhne, C.H., Thuss-Patience, P., Friedrich, M., et al. (1998) Raltitrexed (Tomudex): An Alternative Drug for Patients with Colorectal Cancer and 5-Fluorouracil Associated Cardiotoxicity. British Journal of Cancer, 77, 973-977.
https://doi.org/10.1038/bjc.1998.160
|
[13]
|
Gallois, C., Hafliger, E., Auclin, E., et al. (2022) First-Line Chemotherapy with Ral-titrexed in Metastatic Colorectal Cancer: An Association des Gastro-Entérologues Oncologues (AGEO) Multicentre Study. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 54, 684-691. https://doi.org/10.1016/j.dld.2021.08.009
|
[14]
|
Cucciniello, L., Bidoli, E., Viel, E., et al. (2022) The Puzzling Clinical Presentation of Fluoropyrimidines Cardiotoxicity. Frontiers in Cardiovascular Medicine, 9, Article ID: 960240. https://doi.org/10.3389/fcvm.2022.960240
|
[15]
|
Ladak, I., Preti, B., Dias, B., et al. (2022) Raltitrexed as a Substitute for Capecita-bine in Metastatic Gastric Cancer: A Case Report and Literature Review. Annals of Translational Medicine, 10, 1285. https://doi.org/10.21037/atm-2022-69
|
[16]
|
Avallone, A., Di Gennaro, E., Silvestro, L., et al. (2014) Targeting Thymidylate Syn-thase in Colorectal Cancer: Critical Re-Evaluation and Emerging Therapeutic Role of Raltitrexed. Expert Opinion on Drug Safety, 13, 113-129.
https://doi.org/10.1517/14740338.2014.845167
|
[17]
|
Chen, Y., Wu, J., Cheng, K., et al. (2019) S-1 plus Raltitrexed for Refracto-ry Metastatic Colorectal Cancer: A Phase II Trial. The Oncologist, 24, 591-e165. https://doi.org/10.1634/theoncologist.2018-0901
|
[18]
|
Yamashita, K., Kiyonari, S., Tsubota, S., et al. (2020) Thymidylate Syn-thase Inhibitor Raltitrexed Can Induce High Levels of DNA Damage in MYCN-Amplified Neuroblastoma Cells. Cancer Science, 111, 2431-2439.
https://doi.org/10.1111/cas.14485
|
[19]
|
Liu, B., Zhu, X., Gao, S., et al. (2019) Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin Post-Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Journal of Interventional Medicine, 2, 91-96. https://doi.org/10.1016/j.jimed.2019.07.006
|
[20]
|
Shao, W., Li, C., Tang, J., et al. (2019) Efficacy and Safety of Raltitrexed plus Oxaliplatin-Based Transarterial Chemoembolization in Patients with Unresectable Hepa-tocellular Carcinoma. Cancer Management and Research, 11, 9863-9869. https://doi.org/10.2147/CMAR.S217524
|
[21]
|
Jansson, Y., Graf, W. and Ghanipour, L. (2022) The Prognostic Impact of Lead Times in Colorectal Cancer Patients Undergoing Cytoreductive Surgery and HIPEC. World Journal of Surgical Oncology, 20, 300.
https://doi.org/10.1186/s12957-022-02765-1
|
[22]
|
Gong, Q., Song, C., Wang, X., et al. (2020) Hyperthermic Intraperitoneal Chemotherapy with Recombinant Mutant Human TNF-α and Raltitrexed in Mice with Colorectal-Peritoneal Carcinomatosis. Experi-mental Biology and Medicine (Maywood, NJ), 245, 542-551. https://doi.org/10.1177/1535370220905047
|
[23]
|
Zeng, L., Liao, Q., Zhao, Q., et al. (2021) Raltitrexed as a Synergistic Hyperthermia Chemotherapy Drug Screened in Patient-Derived Colorectal Cancer Organoids. Cancer Biology & Medicine, 18, 750-762.
https://doi.org/10.20892/j.issn.2095-3941.2020.0566
|
[24]
|
Zhou, S., Jiang, Y., Liang, J., et al. (2021) Neoadjuvant Chemotherapy Followed by Hyperthermic Intraperitoneal Chemotherapy for Patients with Colorectal Peritoneal Metastasis: A Retrospective Study of Its Safety and Efficacy. World Journal of Surgical Oncology, 19, 151. https://doi.org/10.1186/s12957-021-02255-w
|
[25]
|
Guo, J.H., Zhang, H.Y., Gao, S., et al. (2017) Hepatic Artery Infusion with Raltitrexed or 5-Fluorouracil for Colorectal Cancer Liver Metas-tasis. World Journal of Gastroenterology, 23, 1406-1411. https://doi.org/10.3748/wjg.v23.i8.1406
|
[26]
|
Yang, X., Li, H., Liu, J., et al. (2021) The Short-Term Efficacy of DEB-TACE Loaded with Epirubicin and Raltitrexed in the Treatment of Intermediate and Ad-vanced Primary Hepatocellular Carcinoma. American Journal of Translational Research, 13, 9562-9569.
|
[27]
|
Rosch, J.G., Landry, M.R., Thomas, C.R., et al. (2019) Enhancing Chemoradiation of Colorectal Cancer through Targeted Delivery of Raltitrexed by Hyalu-ronic Acid Coated Nanoparticles. Nanoscale, 11, 13947-13960.
https://doi.org/10.1039/C9NR04320A
|
[28]
|
Rosch, J.G., DuRoss, A.N., Landry, M.R., et al. (2020) Formulation of Fo-late-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics. Pharmaceutics, 12, 133. https://doi.org/10.3390/pharmaceutics12020133
|
[29]
|
Morey, J., Llinás, P., Bueno-Costa, A., et al. (2021) Raltitrexed-Modified Gold and Silver Nanoparticles for Targeted Cancer Therapy: Cytotoxicity Behavior in Vitro on A549 and HCT-116 Human Cancer Cells. Materials (Basel, Switzerland), 14, 534. https://doi.org/10.3390/ma14030534
|
[30]
|
Yan, P., Yin, H., Guo, W., et al. (2020) Raltitrexed versus 5-Fluorouracil with Cisplatin and Concurrent Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: An Open Labeled, Randomized, Controlled, and Multicenter Clinical Trial. Cancer Medicine, 9, 6166-6172. https://doi.org/10.1002/cam4.3260
|
[31]
|
Wu, Y., Wei, X., Yuan, Z., et al. (2020) Phase II Study of Induction Chemotherapy Fol-lowed by Concurrent Chemoradiotherapy with Raltitrexed and Cisplatin in Locally Advanced Nasopharyngeal Carcinoma. Chinese Journal of Cancer Research, 32, 665-672. https://doi.org/10.21147/j.issn.1000-9604.2020.05.11
|
[32]
|
Leonardi, M.C., Zampino, M.G., Luca, F., et al. (2006) Pre-Operative Radiochemotherapy with Raltitrexed for Resectable Locally-Advanced Rectal Cancer: A Phase II Study. Anticancer Research, 26, 2419-2423.
|
[33]
|
Yoney, A., Askaroglu, B., Hancilar, T., et al. (2008) A Retrospective Comparison of Concurrent Bolus 5-Fluorouracil or Raltitrexed in Preoperative Chemoradiation for Locally Advanced Rectal Cancer. Hematology/Oncology and Stem Cell Therapy, 1, 28-33. https://doi.org/10.1016/S1658-3876(08)50057-4
|
[34]
|
Royer, B., Schmitt, A., Nguyen, T., et al. (2021) Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity. British Journal of Clinical Pharmacology, 87, 1327-1337. https://doi.org/10.1111/bcp.14519
|
[35]
|
Li, Y., Chen, Y., Qiu, C., et al. (2019) 17-Allylamino-17-demethoxygeldanamycin Impeded Chemotherapy through Antioxidant Activation via Reducing Reactive Oxygen Species-Induced Cell Death. Journal of Cellular Biochemistry, 120, 1560-1576. https://doi.org/10.1002/jcb.27397
|
[36]
|
曹淑龙. 雷替曲塞抗结直肠癌的机制及生物学功能研究[D]: [硕士学位论文]. 荆州: 长江大学, 2022.
|
[37]
|
El-Mesallamy, H.O., El Mag-doub, H.M., Chapman, J.M., et al. (2018) Biomolecular Study of Human Thymidylate Synthase Conformer-Selective Inhibitors: New Chemotherapeutic Approach. PLOS ONE, 13, e0193810.
https://doi.org/10.1371/journal.pone.0193810
|